Covered recipient · General Payments record
SHAKIRAYE ROOKWOOD
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2023–2024
$639.69
- Reported across 27 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $428.17 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $161.67 | 7 |
| Novo Nordisk AS | $149.65 | 6 |
| ABBVIE INC. | $60.68 | 2 |
| Acerta Pharma LLC | $35.94 | 2 |
| Agile Therapeutics, Inc. | $20.23 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $30.34 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108111346 | CMS |
| ABBVIE INC. | $30.34 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108111348 | CMS |
| Agile Therapeutics, Inc. | $20.23 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154842845 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.97 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105636324 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.97 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104730659 | CMS |
| Lilly USA, LLC | $30.21 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135962819 | CMS |
| Lilly USA, LLC | $27.46 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135863811 | CMS |
| Lilly USA, LLC | $22.94 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135944888 | CMS |
| Lilly USA, LLC | $16.44 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135935578 | CMS |
| Lilly USA, LLC | $22.86 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135949380 | CMS |
| Lilly USA, LLC | $24.15 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135949382 | CMS |
| Lilly USA, LLC | $17.61 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135863815 | CMS |
| Novo Nordisk Inc | $24.48 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100467882 | CMS |
| Novo Nordisk Inc | $22.37 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100260397 | CMS |
| Novo Nordisk Inc | $21.72 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100657601 | CMS |
| Novo Nordisk Inc | $21.92 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100344192 | CMS |
| Novo Nordisk Inc | $34.81 | 11/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100633685 | CMS |
| Novo Nordisk Inc | $24.35 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100560707 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.